SK bioscience, a South Korea-based vaccine and biotech company, has completed a major expansion of its L HOUSE production facility in Andong to support global supply of its 21-valent pneumococcal conjugate vaccine (PCV) candidate, GBP410. The facility has now received
SK bioscience has acquired a controlling stake in IDT Biologika, a German contract development and manufacturing organization (CDMO), for 339 billion won ($243.9 million). The deal, finalized through an agreement with the Klocke Group, gives SK bioscience 60% of IDT
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups Sign up for our weekly newsletter
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
